These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 21487054)

  • 1. A semiphysiological population model for prediction of the pharmacokinetics of drugs under liver and renal disease conditions.
    Strougo A; Yassen A; Krauwinkel W; Danhof M; Freijer J
    Drug Metab Dispos; 2011 Jul; 39(7):1278-87. PubMed ID: 21487054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Basic concepts of clinical pharmacokinetics.
    Raghuram TC; Krishnaswamy K
    J Assoc Physicians India; 1992 Jan; 40(1):29-35. PubMed ID: 1634460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy.
    Perucca E; Cloyd J; Critchley D; Fuseau E
    Epilepsia; 2008 Jul; 49(7):1123-41. PubMed ID: 18503564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic basis for the safety of glimepiride in risk groups of NIDDM patients.
    Rosenkranz B
    Horm Metab Res; 1996 Sep; 28(9):434-9. PubMed ID: 8911979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physiologically based pharmacokinetics (PBPK).
    Espié P; Tytgat D; Sargentini-Maier ML; Poggesi I; Watelet JB
    Drug Metab Rev; 2009; 41(3):391-407. PubMed ID: 19601719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Drug therapy in liver disease].
    Meier PJ
    Schweiz Med Wochenschr; 1982 Feb; 112(8):258-63. PubMed ID: 7043727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modeling and predicting drug pharmacokinetics in patients with renal impairment.
    Rowland Yeo K; Aarabi M; Jamei M; Rostami-Hodjegan A
    Expert Rev Clin Pharmacol; 2011 Mar; 4(2):261-74. PubMed ID: 22115405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Database for physiologically based pharmacokinetic (PBPK) modeling: physiological data for healthy and health-impaired elderly.
    Thompson CM; Johns DO; Sonawane B; Barton HA; Hattis D; Tardif R; Krishnan K
    J Toxicol Environ Health B Crit Rev; 2009 Jan; 12(1):1-24. PubMed ID: 19117207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study.
    Lal R; Sukbuntherng J; Luo W; Chen D; Blumenthal R; Ho J; Cundy KC
    Clin Ther; 2012 Jan; 34(1):201-13. PubMed ID: 22206794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of unbound volumes of drug distribution in pharmacokinetic calculations.
    Stepensky D
    Eur J Pharm Sci; 2011 Jan; 42(1-2):91-8. PubMed ID: 21050885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and pharmacodynamics of lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal of liver function.
    Welink J; Boven E; Vermorken JB; Gall HE; van der Vijgh WJ
    Clin Cancer Res; 1999 Sep; 5(9):2349-58. PubMed ID: 10499604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disease-induced modifications of drug pharmacokinetics.
    Barre J; Houin G; Brunner F; Bree F; Tillement JP
    Int J Clin Pharmacol Res; 1983; 3(4):215-26. PubMed ID: 6381335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics of raltitrexed in patients with advanced solid tumours.
    Blair EY; Rivory LP; Clarke SJ; McLachlan AJ
    Br J Clin Pharmacol; 2004 Apr; 57(4):416-26. PubMed ID: 15025739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PBPK models in risk assessment--A focus on chloroprene.
    DeWoskin RS
    Chem Biol Interact; 2007 Mar; 166(1-3):352-9. PubMed ID: 17324392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Consequences of renal insufficiency on the hepatic clearance of some drugs.
    Balant LP; Dayer P; Fabre J
    Int J Clin Pharmacol Res; 1983; 3(6):459-74. PubMed ID: 6147317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics and bayesian estimator of cyclosporine in pediatric renal transplant patients.
    Irtan S; Saint-Marcoux F; Rousseau A; Zhang D; Leroy V; Marquet P; Jacqz-Aigrain E
    Ther Drug Monit; 2007 Feb; 29(1):96-102. PubMed ID: 17304156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Some considerations on the predictions of pharmacokinetic alterations in subjects with liver disease.
    Gonzalez M; Goracci L; Cruciani G; Poggesi I
    Expert Opin Drug Metab Toxicol; 2014 Oct; 10(10):1397-408. PubMed ID: 25219632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Introduction to pharmacokinetics in clinical toxicology.
    Vajjah P; Isbister GK; Duffull SB
    Methods Mol Biol; 2012; 929():289-312. PubMed ID: 23007434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Semiphysiological versus empirical modelling of the population pharmacokinetics of free and total cefazolin during pregnancy.
    van Hasselt JG; Allegaert K; van Calsteren K; Beijnen JH; Schellens JH; Huitema AD
    Biomed Res Int; 2014; 2014():897216. PubMed ID: 24672799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of the Effect of Renal Impairment on the Pharmacokinetics of New Drugs.
    Borella E; Poggesi I; Magni P
    Clin Pharmacokinet; 2018 Apr; 57(4):505-514. PubMed ID: 28667460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.